Literature DB >> 16255632

Telomerase: is it the future diagnostic and prognostic tool in human cancer?

Mohamed J E M F Mabruk1, Cathal O'Flatharta.   

Abstract

A number of methods exist to detect levels of telomerase activity and the presence of telomerase subunits in a variety of tissues. As telomerase activation seems to be an important step in tumorigenesis, accurate detection of the presence and activity of the enzyme and its subunits is vital. The original method of detecting telomerase activity was developed by Kim and coworkers in 1994, and was termed the telomeric repeat amplification protocol. This assay led to a staggering increase in the number of telomerase-associated publications in scientific journals (85 publications from 1974-1994, 5063 publications from 1994-2004). A number of methods have been described to detect telomeres and to measure their length, with the standard measurement of telomere length performed using a modification of the Southern blot protocol. RNA in situ hybridization can be performed to detect levels of the RNA component of telomerase, and standard in situ hybridization and immunohistochemistry can be applied to examine expression levels and localization of the catalytic subunit of the enzyme. Reverse transcriptase PCR has also been applied to assess expression levels of the telomerase components in various tissues. This review provides a synopsis of telomeres, telomerase, telomerase and cancer, and finally, methods for the detection of telomerase in cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16255632     DOI: 10.1586/14737159.5.6.907

Source DB:  PubMed          Journal:  Expert Rev Mol Diagn        ISSN: 1473-7159            Impact factor:   5.225


  4 in total

1.  Expression of telomeres in astrocytoma WHO grade 2 to 4: TERRA level correlates with telomere length, telomerase activity, and advanced clinical grade.

Authors:  Sandra Sampl; Sibylle Pramhas; Christian Stern; Matthias Preusser; Christine Marosi; Klaus Holzmann
Journal:  Transl Oncol       Date:  2012-02-01       Impact factor: 4.243

2.  Circulating hTERT mRNA as a tumor marker in cholangiocarcinoma patients.

Authors:  Kawin Leelawat; Surang Leelawat; Thawee Ratanachu-Ek; Somboon Trubwongchareon; Jerasak Wannaprasert; Saad Tripongkaruna; Suchart Chantawibul; Panadda Tepaksorn
Journal:  World J Gastroenterol       Date:  2006-07-14       Impact factor: 5.742

3.  hTERT expression in colorectal adenocarcinoma: correlations with p21, p53 expressions and clinicopathological features.

Authors:  Alfred King-Yin Lam; Kate Ong; Yik-Hong Ho
Journal:  Int J Colorectal Dis       Date:  2008-03-06       Impact factor: 2.571

4.  miR-512-5p suppresses tumor growth by targeting hTERT in telomerase positive head and neck squamous cell carcinoma in vitro and in vivo.

Authors:  Jun Li; Han Lei; Yong Xu; Ze-Zhang Tao
Journal:  PLoS One       Date:  2015-08-10       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.